Evidence map›Paper›PMID 39616585›Full record

ArticleClinical journal of gastroenterology2025

A case of complete remission by cabozantinib as an end-line treatment for advanced hepatocellular carcinoma.

Shuhei Nagashima, Satoshi Kobayashi, Shotaro Tsunoda, Yui Yamachika, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shuhei NagashimaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan. shuhei.nagashima@gmail.com.ORCID http://orcid.org/0000-0001-9862-7861
Satoshi KobayashiDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Shotaro TsunodaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Yui YamachikaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Yuichiro TozukaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Taito FukushimaDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Manabu MorimotoDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Makoto UenoDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Junji FuruseDepartment of Gastroenterology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, 241-8515, Japan.
Shin MaedaDepartment of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9, Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cabozantinib is a multi-kinase inhibitor targeting multiple tyrosine kinases. It improves overall survival and progression-free survival in patients previously treated with sorafenib for advanced hepatocellular carcinoma (HCC) compared to the placebo in the phase 3 CELESTIAL trial. A 71-year-old man presented to our hospital for treatment of HCC with chronic hepatitis C. He was refractory to sorafenib, lenvatinib, regorafenib, and ramucirumab and started atezolizumab and bevacizumab therapy in November 2020. After administering the second cycle on December 10, 2020, the patient was diagnosed with progressive disease in January 2021. Therefore, cabozantinib (60 mg/day) was initiated on January 14, 2021. As the grade 3 aspartate aminotransferase and alanine aminotransferase levels increased, grade 3 anorexia and a decline in performance status were observed in the first week, and cabozantinib was terminated. His performance status and anorexia gradually improved, and contrast-enhanced computed tomography (CT) in June 2021 showed complete remission (CR) according to the modified Response Evaluation Criteria in Solid Tumors. The patient did not show disease progression for 11 months without receiving any treatment for HCC. To the best of our knowledge, this is the first report of CR with cabozantinib in advanced HCC.

Indexed as

AnilidesAntineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsProtein Kinase InhibitorsPyridinesAgedHumansMaleRemission InductionAnilidesAntineoplastic AgentscabozantinibProtein Kinase InhibitorsPyridinesCabozantinibComplete remissionHepatocellular carcinomaImmune checkpoint inhibitor

Identifiers

PMID39616585
PMCPMC11785699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.